Increased STAT-3 and synchronous activation of Raf-1-MEK-1-MAPK, and phosphatidylinositol 3-Kinase-Akt-mTOR pathways in atypical and anaplastic meningiomas

Journal of Neuro-Oncology

Volumn 92, Issue 2, 2009, Pages 129-136

  Johnson, Mahlon D ^a   O'Connell, Mary ^a   Vito, Fran ^a   Bakos, Robert S ^b  

^a UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^b UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

Author keywords

Meningioma; p Akt; p MAPK; p MTOR; p PRAS40; p STAT3

Indexed keywords

MAMMALIAN TARGET OF RAPAMYCIN; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE KINASE 1; ONCOPROTEIN; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; PROTEIN PRAS40; RAF PROTEIN; STAT3 PROTEIN; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER GRADING; CANCER TISSUE; CONTROLLED STUDY; ENZYME ACTIVATION; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; MENINGIOMA; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; WESTERN BLOTTING; WORLD HEALTH ORGANIZATION;

1-PHOSPHATIDYLINOSITOL 3-KINASE; BLOTTING, WESTERN; HUMANS; IMMUNOHISTOCHEMISTRY; MAP KINASE KINASE 1; MENINGEAL NEOPLASMS; MENINGIOMA; MITOGEN-ACTIVATED PROTEIN KINASE KINASES; PHOSPHORYLATION; PROTEIN KINASES; PROTO-ONCOGENE PROTEINS C-AKT; PROTO-ONCOGENE PROTEINS C-RAF; SIGNAL TRANSDUCTION; STAT3 TRANSCRIPTION FACTOR;

EID: 61349084198     PISSN: 0167594X     EISSN: 15737373     Source Type: Journal    
DOI: 10.1007/s11060-008-9746-7     Document Type: Article

References (46)

1. Johnson M, Toms S (2006) Mitogenic signal transduction pathways in meningiomas: Novel targets for meningioma chemotherapy? J Neuropathol Exp Neurol 64:1029-1036. doi: 10.1097/01.jnen.0000189834.63951.81
2. Norden AD, Drappatz J, Wen PY (2007) Targeted drug therapy for meningiomas. Neurosurg Focus 23:1-12. doi: 10.3171/FOC-07/10/E12
3. Johnson MD, Horiba M, Arteaga C (1994) The epidermal growth factor receptor is associated with phospholipase C γ in meningiomas. Hum Pathol 25:146-153. doi: 10.1016/0046-8177(94)90270-4
4. Johnson MD, Woodard A, Kim P, Frexes-Steed M (2001) Evidence for mitogen associated protein kinase activation and transduction of mitogenic signals from platelet derived growth factor in human meningioma cells. J Neurosurg 94:303-310
5. Johnson MD, Okediji E, Woodard A, Toms SA (2002) Evidence for phosphatidylinositol 3-kinase Akt-p70 S6K pathway activation and transduction of mitogenic signals by platelet derived growth factor in human meningioma cells. J Neurosurg 97:668-675
6. Bromberg J (2002) STAT proteins and oncogenesis. J Clin Invest 109:1139-1142
7. Johanson CE, Duncan JA III, Klinge PM, Brinker T, Stopa EG, Silverberg GD (2008) Multiplicity of cerebrospinal fluid functions: New challenges in health and Disease. Cerebrospinal Fluid Res 5:10. doi: 10.1186/ 1743-8454-5-10
8. Jones NR, Rossi ML, Gregoriou M, Hughes JT (1990) Epidermal growth factor receptor expression in 72 meningiomas. Cancer 66:152-155. doi:10.1002/ 1097-0142(19900701)66:1<152::AID-CNCR2820660127>3.0.CO;2-5
9. Weisman AS, Raguet SS, Kelly PA (1987) Characterization of the epidermal growth factor receptor in human meningioma. Cancer Res 47:2172-2176
10. Maxwell M, Galanopoulos T, Hedley-Whyte ET, Black PML, Antoniades HN (1990) Human meningiomas co-express platelet-derived growth factor (PDGF) and PDGF-receptor genes and their protein products. Int J Cancer 46:16-21. doi: 10.1002/ijc.2910460106
11. Shamah SM, Alberta JA, Giannobile WV, Guha A, Kwon YK, Carroll RS, Black PM, Stiles CD et al (1997) Detection of activated platlet-derived growth factor receptors in human meningioma. Cancer Res 57:4141-4147
12. Adams EF, Schrell UMH, Thieruf P, White MC, Fahlbusch R (1991) Autocrine control of human meningioma proliferation: Secretion of platelet-derived growth factor-like molecules. Int J Cancer 49:398-402. doi: 10.1002/ ijc.2910490315
13. Nordqvist AC, Peyrard M, Petterson H et al (1997) A high ratio of insulin-like growth factor II/insulin-like growth factor binding protein 2 messenger RNA as a marker for anaplasia in meningiomas. Cancer Res 57:2611-2614
14. Watson MA, Gutmann DH, Peterson K et al (2002) Molecular characterization of human meningiomas by gene expression profiling using high-density oligonucleotide microarrays. Am J Pathol 161:665-672
15. Magrassi L, De-Fraja C, Conti L, Butti G, Infuso L, Govoni S et al (1999) Expression of the JAK and STAT superfamilies in human meningiomas. J Neurosurg 91:440-446
16. Mawrin C, Sasse T, Kirches E, Kropf S, Schneider T, Grimm C et al (2005) Different activation of mitogen activated protein kinase and Akt signalling is associated with aggressive phenotype of human meningiomas. Clin Cancer Res 11:4074-4082. doi: 10.1158/1078-0432.CCR-04-2550
17. Perry A, Louis DN, Scheithauer BW, Budka H, von Deimling A (2007) Meningiomas. In: Louis DN, Ohgaki H, Wiestler OD, Cavenee WK (eds) Tumours of the nervous system. WHO Press, Geneva, Switzerland, pp 164-172
18. Klampfer L (2006) Signal transducers and activators of transcription (STATs): Novel targets of chemopreventive and chemotherapeutic drugs. Curr Cancer Drug Targets 6:107-121. doi: 10.2174/156800906776056491
19. Kortylewski M, Hua Y (2007) Stat3 as a potential target for cancer immunotherapy. J Immunother 30:131-139. doi: 10.1097/ 01.cji.0000211327.76266.65
20. Germain D, Frank DA (2007) Targeting the cytoplasmic and nuclear functions of signal transducers and activators of transcription 3 for cancer therapy. Clin Cancer Res 13:5665-5669. doi: 10.1158/ 1078-0432.CCR-06-2491
21. Silva CM (2004) Role of STATs as downstream signal transducers in Src family kinase-mediated tumorigenesis. Oncogene 23:8017-8023. doi: 10.1038/sj.onc.1208159
22. Garcia R, Bowman TL, Niu G et al (2001) Constitutive activation of Stat3 by the Src and JAK tyrosine kinases participates in growth regulation of human breast carcinoma cells. Oncogene 20:2499-2513. doi: 10.1038/ sj.onc.1204349
23. Kohno M, Pouyssegur J (2006) Targeting the ERK signaling pathway in cancer therapy. Ann Med 38:200-211. doi: 10.1080/07853890600551037
24. McKay MM, Morrison DK (2007) Integrating signals from RTKs to ERK/MAPK. Oncogene 26:3113-3121. doi: 10.1038/sj.onc.1210394
25. Yoon S, Seger R (2006) The extracellular signal-regulated-kinase: multiple substrates regulate diverse cellular functions. Growth Factors 24:21-44. doi: 10.1080/02699050500284218
26. Barnett SF, Bilodeau MT, Lindsley CW (2005) The Akt/PKB family of protein kinases: A review of small molecule inhibitors and progress toward target validation. Curr Top Med Chem 5:109-125. doi: 10.2174/ 1568026053507714
27. Shayesteh L, Lu Y, Kuo W-L, Baldocchi R, Godfrey T, Collins C et al (1999) PIK3CA is implicated as an oncogene in ovarian cancer. Nat Genet 21:99-102. doi: 10.1038/5042
28. Sun M, Wang G, Paciga JE, Feldman RI, Yuan ZQ, Ma XL et al (2001) AKT1/ PKB alpha kinase is frequently elevated in human cancers and its constitutive activation is required for oncogenic transformation in NIH3T3 cells. Am J Pathol 159:431-437
29. Vivanco I, Sawyers CL (2002) The phosphatidylinositol 3-kinase-AKT pathway in human cancer. Cell Signal 14:381-395. doi: 10.1016/ S0898-6568(01)00271-6
30. Crowell JA, Steele VE, Fay JR (2007) Targeting the Akt protein kinase for cancer prevention. Mol Cancer Ther 6:2319-2418. doi: 10.1158/ 1535-7163.MCT-07-0120
31. Brognard J, Clark AS, Ni Y, Dennis PA (2001) Akt/protein kinase B is constitutively active in non-small cell lung cancer cells and promotes cellular survival and resistance to chemotherapy and radiation. Cancer Res 61:3986-3997
32. Roymans D, Slegers H (2001) Phosphatidylinositol 3-kinases in tumor progression. Eur J Biochem 268:487-498. doi: 10.1046/ j.1432-1327.2001.01936.x
33. Kovacina KS et al (2003) Identification of a praline rich Akt substrate as a 14-3-3 binding partner. J Biol Chem 278:10189-10194. doi: 10.1074/ jbc.M210837200
34. Mamane Y, Petroulakis E, LeBacquer O, Sonenberg N (2006) MTOR, translation intiation and cancer. Oncogene 25:6416-6422. doi: 10.1038/ sj.onc.1209888
35. Sabatini DM (2006) mTOR and cancer: Insights into a complex relationship. Natl Rev 6:729-734
36. Arteaga CL (2002) Epidermal growth factor dependence in human tumors: more than just expression? Oncologist 7:31-39. doi: 10.1634/ theoncologist.7-suppl_4-31
37. Paez JG, Janne PA, Lee JC, Tracy S, Greulich H, Herman P et al (2004) EGFR mutations in lung cancer: Correlation with clinical response to Gefitinib therapy. Science 304:1497-1500. doi: 10.1126/science.1099314
38. Witzig TE, Kaufmann SH (2006) Inhibition of the phosphatidylinositol 3-kinase/mammalian target of rapamycin pathway in hematologic malignancies. Curr Treat Options Oncol 7:285-294. doi: 10.1007/ s11864-006-0038-1
39. Madhunapantula SV, Sharma A, Robertson GP (2007) PRAS40 deregulates apoptosis in malignant melanoma cells. Cancer Res 67:3626-3636. doi: 10.1158/0008-5472.CAN-06-4234
40. Gire V, Marshall C, Wynford-Thomas D (2000) PI-3-kinase is an essential anti-apoptotic effector in the proliferative response of primary human epithelial cells to mutant RAS. Oncogene 19:2269-2276. doi: 10.1038/ sj.onc.1203544
41. Walker TR, Moore SM, Lawson MF, Panettieri RA, Chilvers ER (1998) Platelet-derived growth factor-BB and thrombin activate phophoinositide 3-kinase and protein kinase B: Role in mediating airway smooth muscle proliferation. Mol Pharmacol 54:1007-1015
42. Faivre S, Djelloul S, Raymond E (2006) New paradigms in anticancer therapy: Targeting multiple signaling pathways with kinase inhibitors. Semin Oncol 33:407-420. doi: 10.1053/j.seminoncol.2006.04.005
43. Stommel JM, Kimmelman AC, Ying H et al (2007) Coactivation of receptor tyrosine kinases affects the response of tumor cells to targeted therapies. Science 318:287-290. doi: 10.1126/science.1142946
44. Saxena NK, Sharma D, Ding X, Lin S, Marra F, Merlin D et al (2007) Concomitant activation of the JAK/STAT, PI3K/AKT, and ERK signaling is involved in leptin-mediated promotion of invasion and migration of heptocellular carcinomas cells. Cancer Res 67:2497-2507. doi: 10.1158/ 0008-5472.CAN-06-3075
45. Nakamura JL, Karlsson A, Arvold ND, Gottschalk Ar, Pieper RO, Stokoe D et al (2005) PKB/Akt mediates radiosensitization by signaling inhibitor LY294002 in human malignant gliomas. J Neurooncol 71:215-222. doi: 10.1007/s11060-004-1718-y
46. Wang MY, Lu KV, Dia EQ et al (2006) Mammalian target of rapamycin inhibition promotes response to epidermal growth factor receptor kinase inhibitors in PTEN-deficient and PTEN intact glioblastoma cells. Cancer Res 66:7864-7869. doi: 10.1158/0008-5472.CAN-04-4392